Clinical Trial Update: Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating furmonertinib plus radiotherapy for EGFR-positive non-small cell lung cancer with malignant pleural effusion; currently not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion
• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Jiangmen Central Hospital | Conditions: Lung Cancer (NSCLC), Malignant Pleural Effusions (Mpe)- Pleurodesis | Phase 2 | Status: NOT_YET_RECRUITING